RxDoctor Payments Data

Kristyn Holmes

Nurse Practitioner · Butler, PANPI 1003473414

Payments from drug & device makers

$6,082in general payments, 2019–2025

Across 251 payments — averaging $24.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Inspire Medical Systems, Inc.$2K
  • AstraZeneca$1K
  • Regeneron Healthcare Solutions, Inc.$754
  • GSK$646
  • Grifols USA, LLC$339
  • Takeda Pharmaceuticals U.S.A., Inc.$154
  • plus $1K from 17 others

What the payments were for

  • Travel & lodging$74612%
  • Food & beverage$5,17185%
  • Education$1653%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,082 in reported general payments places this provider in the 95th percentile of 4,059 nurse practitioner providers in Pennsylvania.

See all nurse practitioner providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$13,763
Medicare patients
84
Services billed
152

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter311$232,194
Breo ElliptaFluticasone/Vilanterol133$63,204
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr109$61,094
Spiriva RespimatTiotropium Bromide74$42,483
Stiolto RespimatTiotropium Br/Olodaterol Hcl45$28,812
Breztri AerosphereBudesonide/Glycopyr/Formoterol19$16,705
Fluticasone-SalmeterolFluticasone Propion/Salmeterol68$10,222
Spiriva HandihalerTiotropium Bromide11$7,591
DuleraMometasone/Formoterol12$6,150
Albuterol Sulfate HfaAlbuterol Sulfate233$6,041
Incruse ElliptaUmeclidinium Bromide14$4,681
SymbicortBudesonide/Formoterol Fumarate15$3,366
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate18$2,862
Roflumilast20$2,692
Montelukast Sodium208$2,114

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta$646$361,172567 claims
Boehringer IngelheimSpiriva Respimat, Stiolto Respimat$140$71,295119 claims
AstraZenecaBreztri Aerosphere, Symbicort$1,325$20,07134 claims
MerckDulera$51$6,15012 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,059 nurse practitioner providers in Pennsylvania.

Other nurse practitioner in Butler

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →